Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst

Key Points

• HC Wainwright raised Inovio Pharmaceuticals’ Q3 2026 EPS estimate to a loss of $0.20 per share from a previous estimate of $0.24, while maintaining a “Neutral” rating.
• Analyst sentiment is mixed but generally positive: Inovio has a consensus “Moderate Buy” rating and a $3.17 price target, with Jefferies recently raising its target to $3.00 and upgrading the stock to “Positive.”
• Inovio reported a Q2 loss of $0.07 per share, beating the consensus estimate for a $0.22 loss. The stock opened at $1.09, compared with a 12-month range of $0.56 to $2.98.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - Stock analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for Inovio Pharmaceuticals in a research note issued on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.20) per share for the quarter, up from their prior estimate of ($0.24). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Inovio Pharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.21) EPS.

Other research analysts have also recently issued research reports about the stock. Piper Sandler reaffirmed an "overweight" rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Weiss Ratings downgraded Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday. Zacks Research upgraded Inovio Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 12th. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Jefferies Financial Group upgraded Inovio Pharmaceuticals from a "hold" rating to a "positive" rating and boosted their price target for the company from $1.80 to $3.00 in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inovio Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $3.17.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $1.09 on Monday. The company has a market cap of $112.71 million, a PE ratio of -1.20 and a beta of 1.52. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.98. The company's 50 day moving average is $1.03 and its two-hundred day moving average is $1.30.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in INO. BlackRock Inc. lifted its position in Inovio Pharmaceuticals by 0.9% during the second quarter. BlackRock Inc. now owns 18,709,432 shares of the biopharmaceutical company's stock valued at $767,648,000 after purchasing an additional 167,212 shares during the period. Janus Henderson Group PLC grew its position in Inovio Pharmaceuticals by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company's stock worth $5,773,000 after purchasing an additional 42,146 shares during the period. Vanguard Group Inc. grew its position in Inovio Pharmaceuticals by 35.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company's stock worth $6,348,000 after purchasing an additional 703,727 shares during the period. Millennium Management LLC raised its stake in shares of Inovio Pharmaceuticals by 468.7% during the 3rd quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company's stock valued at $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Finally, Eversept Partners LP purchased a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at about $1,802,000. Institutional investors and hedge funds own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source